SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Bartlett who wrote (7741)10/5/2001 2:47:38 AM
From: Cal Gary  Read Replies (1) of 14101
 
Indirectly WF10 - hivinsite.ucsf.edu

Hi Mark, I'm mark-ing time and found this. Seems to be a comprehensive site. I'll be reading articles here while flipping back to the DMX annual report, pdf version.

hivinsite.ucsf.edu Scroll down to item 141, or directly at
hivinsite.ucsf.edu

Home > Medical > Trials Search > All Open Trials

HIV Infection: WF10

Title: WF10-97-US-004: A Multicenter, Randomized, Double-Blind,
Placebo-Controlled Pivotal Clinical Study Evaluating the Safety and Efficacy of
WF10 (TCDO) Intravenous Solution in the Management of Patients with
Late-Stage HIV Disease

Purpose: To see if WF10 has any effect on the survival of patients with late-stage
HIV disease. To see if WF10 has any effect on disease progression and on the
quality of life.

About the study: Participants are assigned by chance to receive WF10 or
placebo (saline). WF10 and placebo are given by infusion into a vein for five
consecutive days followed by 16 days of rest (one cycle). Participants will receive
four consecutive cycles of treatment. The treatment period lasts eleven weeks.
Study visits are at Week 18, then every three months starting at Week 24 and
lasting through the first year. Study visits are every six months during the second
year. The study lasts for two years.

Required:

HIV-positive
At least 18 years old
CD4 cell (T-cell) range: 50 or less
Viral load range: any
Must have stable (no changes) anti-HIV treatment for at least 30 days prior to
study entry

Not Allowed:

Prenancy or breastfeeding
Current use of interleukins, interferons, G-CSF, GM-CSF, immunoglobulins,
cyclosporins or methotrexate
Any cancers requiring chemotherapy

Locations in District Of Columbia:

Washington:

George Washington
University Medical Center

Suzanne Schuck, RN, BSN
202-994-2417

Locations in Illinois:

Chicago:

Northwestern University
Medical School

Baiba Berzins, MPH
312-908-9636

Locations in New Mexico:

Albuquerque:

Partners in Research/New
Mexico

Mandy Ferguson
505-272-9390

Locations in Utah:

Salt Lake City:

University of Utah School of
Medicine

Kathleen Smith
801-581-6791

Locations in Virginia:

Hampton:

Hampton Roads Medical
Specialists

Susanna Berelovich
757-838-8677
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext